Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-19 in r/r DLBCL
NCT05715606Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in diffuse large B-cell lymphoma (DLBCL), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 3 months. Status: unknown.
02
Drugs
Meta10-19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05715606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715606.